Investment in antiviral drugs: A real options approach

Health Economics

Volumn 19, Issue 10, 2010, Pages 1240-1254

  Attema, Arthur E ^a,b   Lugnér, Anna K ^a   Feenstra, Talitha L ^a,c  

^a NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Antiviral drugs; Decision under uncertainty; Real options analysis

Indexed keywords

ANTIVIRUS AGENT; OSELTAMIVIR;

ASIAN INFLUENZA; COST BENEFIT ANALYSIS; COST OF ILLNESS; DECISION MAKING; DRUG COST; GOVERNMENT; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH CARE UTILIZATION; INFLUENZA A (H1N1); INFLUENZA A (H5N1); INVESTMENT; MODEL; MORTALITY; OUTCOME ASSESSMENT; PANDEMIC INFLUENZA; PRIORITY JOURNAL; PROBABILITY; PUBLIC HEALTH; REVIEW; RISK ASSESSMENT; SEASONAL INFLUENZA; SPANISH INFLUENZA; UNCERTAINTY;

ANTIVIRAL AGENTS; COSTS AND COST ANALYSIS; HEALTH SERVICES; HUMANS; INFLUENZA, HUMAN; MODELS, ECONOMIC; PANDEMICS; RISK ASSESSMENT; TIME FACTORS; UNCERTAINTY;

EID: 77957329660     PISSN: 10579230     EISSN: 10991050     Source Type: Journal    
DOI: 10.1002/hec.1549     Document Type: Review

References (43)

1. Abdellaoui M. 2000. Parameter-free elicitation of utility and probability weighting functions. Management Science 46: 1497-1512.
2. Balicer RD, Huerta M, Davidovitch N, Grotto I. 2005. Cost-benefit of stockpiling drugs for influenza pandemic. Emerging Infectious Diseases 11(8): 1280-1282. (Pubitemid 41045338)
3. Bertsekas DP. 1976. Dynamic Programming and Stochastic Control. Academic Press: New York.
4. Beutels P, Edmunds WJ, Smith RD. 2008. Partially wrong? Partial equilibrium and the economic analysis of public health emergencies of international concern. Health Economics 17(11): 1317-1322.
5. Bleichrodt H, Pinto JL, Wakker PP. 2001. Making descriptive use of prospect theory to improve the prescriptive use of expected utility. Management Science 47: 1498-1514.
6. Bollen NPB. 1999. Real options and product life cycles. Management Science 45: 670-684.
7. Briggs AH, Gray AM. 1999. Handling uncertainty when performing economic evaluation of healthcare interventions. Health Technology Assessment 3(2): 1-134.
8. Casparie AF, van Hout BA, Simoons ML. 1998. Richtlijnen en kosten. Nederlands Tijdschrift voor Geneeskunde 142: 2075-2077 (in Dutch).
9. CBS. Harmonized Consumer Price Index. Available at: http://statline.cbs. nl/statweb/ [15 September 2008].
10. Claxton K. 1999. The irrelevance of inference: a decision making approach to the stochastic evaluation of health care technologies. Journal of Health Economics 18: 341-364. (Pubitemid 29242816)
11. CvZ. 2006. Guidelines for Pharmacoeconomic Research. College voor Zorgverzekeringen: Diemen.
12. Dixit AK, Pindyck RS. 1994. Investment Under Uncertainty. Princeton University Press: Princeton.
13. Driffield T, Smith PC. 2007. A real options approach to watchful waiting: theory and an illustration. Medical Decision Making 27: 178-188. (Pubitemid 46568907)
14. Dunn FL. 1958. Pandemic influenza in 1957. Journal of American Medical Association 166(10): 1140-1148.
15. Eckermann S, Willan AR. 2008. The option value of delay in health technology assessment. Medical Decision Making 28(3): 300-305. (Pubitemid 351713293)
16. Ekern S. 1988. An option pricing approach to evaluating petroleum projects. Energy Economics 10: 91-99.
17. Fenichel EP, Tsao JI, Jones ML, Hickling GJ. 2008. Real options for precautionary fisheries management. Fish and Fisheries 9(2): 121-137. (Pubitemid 351670264)
18. Fenwick E, Palmer S, Claxton K, Sculpher M, Abrams K, Sutton A. 2006. An iterative Bayesian approach to health technology assessment: application to a policy of pre-operative optimisation for patients undergoing major elective surgery. Medical Decision Making 26(5): 480-496. (Pubitemid 44410298)
19. Gollier C, Treich N. 2003. Decision-making under scientific uncertainty: the economics of the precautionary principle. The Journal of Risk and Uncertainty 27(1): 77-103.
20. Health Council of the Netherlands. 2005. Use of Antiviral Agents and Other Measures in an Influenza Pandemic. Health Council of the Netherlands, publication no. 2005/05: The Hague (in Dutch).
21. Holt CA, Laury SK. 2002. Risk aversion and incentive effects. American Economic Review 92(5): 1644-1655.
22. Hugonnier J, Morellec E. 2007. Real options and risk aversion. Swiss Finance Institute Research Paper. Available at: http://ssrn.com/abstract=422600, DOI: 10.2139/ssrn.422600.
23. Johnson NP, Mueller J. 2002. Updating the accounts: global mortality of the 1918-1920 'Spanish' influenza pandemic. Bulletin of the History of Medicine 76(1): 105-120.
24. Kahneman D, Tversky T. 1979. Prospect theory: an analysis of decision under risk. Econometrica 47(2): 263-291.
25. Kelly S. 1998. A binomial lattice approach for valuing a mining property IPO. Quarterly Review of Economic Finance 38: 693-709. (Pubitemid 128180047)
26. Koopmanschap MA, Rutten FFH, van Ineveld BM, van Roijen L. 1995. The friction cost method for measuring indirect cost of disease. Journal of Health Economics 14(2): 171-189.
27. Lee VJ, Hong Phua K, Chen MI, Chow A, Ma S, Tai Goh K, Sin Leo Y. 2006. Economics of neuroaminidase inhibitor stockpiling for pandemic influenza, Singapore. Emerging Infectious Diseases 12(1): 95-102. (Pubitemid 43143543)
28. Lugnér AK, Postma MJ. 2009. Investment decisions in influenza pandemic contingency planning: cost-effectiveness of stockpiling antiviral drugs. European Journal of Public Health, DOI: 10.1093/eurpub/ckp119.
29. Lugnér AK, Mylius SD, Wallinga J. 2009. Dynamic versus static models in cost-effectiveness analyses of anti-viral drug therapy to mitigate an influenza pandemic. Health Economics, DOI: 10.1002/hec.1485.
30. Mylius SD, Hagenaars TJ, Lugnér AK, Wallinga J. 2008. Optimal allocation of pandemic vaccine depends on age, risk and timing. Vaccine 26: 3742-3749.
31. Nguyen-Van-Tam JS, Hampson AW. 2003. The epidemiology and clinical impact of pandemic influenza. Vaccine 21(16): 1762-1768.
32. Oostenbrink J, Bouwmans CAM, Koopmanschap MA, Rutten FFH. 2004. Handleiding voor kostenonderzoek, methoden en standaard kostprijzen voor economische evaluaties in de gezondheidszorg. College voor Zorgverzekeringen: Amstelveen (in Dutch).
33. Palmer S, Smith PC. 2000. Incorporating option values into the economic evaluation of health care technologies. Journal of Health Economics 19: 755-766.
34. Pennings E, Lint O. 1997. The option value of advanced R&D. European Journal of Operational Research 103(1): 83-94.
35. Postma MJ, Jansema P, Scheijbeler HWKFH, van Genugten MLL. 2005. Scenarios on costs and savings of influenza treatment and prevention for Dutch healthy working adults. Vaccine 23: 5365-5371. (Pubitemid 41579307)
36. Siddiqui MR, Edmunds WJ. 2008. Cost-effectiveness of antiviral stockpiling and near-patient testing for potential influenza pandemic. Emerging Infectious Diseases 4(2): 267-274.
37. Starmer C. 2000. Developments in non-expected utility theory: the hunt for a descriptive theory of choice under risk. Journal of Economic Literature 38(2): 332-382.
38. Trigeorgis L. 1996. Real Options: Managerial Flexibility and Strategy in Resource Allocation. MIT Press: Cambridge.
39. Tversky A, Kahneman D. 1992. Advances in prospect theory: cumulative representation of uncertainty. Journal of Risk and Uncertainty 5: 297-323.
40. van den Goorbergh RWJ, Huisman KJM, Kort PM. 2003. Risk aversion, price uncertainty and irreversible investments. University of Tilburg Discussion paper 2003-119.
41. Wakker PP. 2008. Explaining the characteristics of the power (CRRA) utility family. Health Economics 17(12): 1329-1344.
42. Webby RJ, Webster RG. 2003. Are we ready for pandemic influenza? Science 302(5650): 1519-1522.
43. WHO. 2005. Department of Communicable Disease Surveillance and Response. WHO global influenza preparedness plan: the role of WHO and recommendations for national measures before and during pandemics. Report WHO/CDS/CSR/GIP/2005.5. World Health Organization: Geneva.